BRISTOL-MYERS SQUIBB COMPANY Restructuring Reserve, Period Increase (Decrease)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Restructuring Reserve, Period Increase (Decrease) of $36.00 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReservePeriodIncreaseDecrease · last filed 2019-10-31
- BRISTOL-MYERS SQUIBB COMPANY restructuring reserve, period increase (decrease) for the quarter ending 2019-09-30 was $9.00M, a 80.85% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY restructuring reserve, period increase (decrease) for the quarter ending 2019-06-30 was $12.00M, a 70.73% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY restructuring reserve, period increase (decrease) for the quarter ending 2019-03-31 was $15.00M, a 25.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY restructuring reserve, period increase (decrease) for the quarter ending 2018-12-31 was $40.00M.
- BRISTOL-MYERS SQUIBB COMPANY restructuring reserve, period increase (decrease) for fiscal 2018 was $148.00M, a 53.61% decline from fiscal 2017.
- BRISTOL-MYERS SQUIBB COMPANY restructuring reserve, period increase (decrease) for fiscal 2017 was $319.00M, a 175.00% increase from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY restructuring reserve, period increase (decrease) for fiscal 2016 was $116.00M.
| Period end | Restructuring Reserve, Period Increase (Decrease) 3 month | Restructuring Reserve, Period Increase (Decrease) 6 month | Restructuring Reserve, Period Increase (Decrease) 9 month | Restructuring Reserve, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $21.00M derived: sum of 2 quarters · filed 2019-10-31 | $36.00M 10-Q · filed 2019-10-31 | $76.00M derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $27.00M 10-Q · filed 2019-07-25 | $67.00M derived: sum of 3 quarters · filed 2019-07-25 | $114.00M derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-03-31 | $15.00M 10-Q · filed 2019-04-25 | $55.00M derived: sum of 2 quarters · filed 2019-04-25 | $102.00M derived: sum of 3 quarters · filed 2019-10-31 | $143.00M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $87.00M derived: sum of 2 quarters · filed 2019-10-31 | $128.00M derived: sum of 3 quarters · filed 2019-10-31 | $148.00M 10-K · filed 2019-02-25 |
| 2018-09-30 | $47.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $88.00M derived: sum of 2 quarters · filed 2019-10-31 | $108.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $41.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $61.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | $20.00M 10-Q · filed 2019-04-25 | |||
| 2017-12-31 | $319.00M 10-K · filed 2019-02-25 | |||
| 2016-12-31 | $116.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |